Nicolas Johannes Mueller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nicolas Johannes Mueller has a total of 582 co-authors. Here are the top co-authors by number of shared publications:
- Oriol Manuel
Infectious Diseases Service Lausanne University Hospital and University of Lausanne Lausanne Switzerland
19 shared publications Christian Garzoni
Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland
12 shared publicationsChristian van Delden
11 shared publicationsKatia Boggian
Division of Infectious Diseases, Cantonal Hospital St Gallen, St Gallen, Switzerland
11 shared publications- Cédric Hirzel
Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
10 shared publications - Dionysios Neofytos
Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
10 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Wiley in Transplant Infectious Disease
Prophylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study
Background: The optimal duration of cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients (SOTr) remains undetermined. We evaluated real‐life preventive strategies on the incidence of CMV disease in an international SOTr cohort. Methods: All CMV IgG donor (D)+/recipient (R)− or R+ SOTr in Zürich, Lausanne, and Copenhagen (2008–2022) were followed 12‐month post‐transplantation. Multivariable Poisson regression examined associations between antiviral prophylaxis duration and risk of CMV infection and CMV disease at time of infection diagnosis. Results: We included 3203 non‐lung (2057 kidney, 815 liver, 331 heart) and 620 lung transplant recipients. Strategies for CMV prophylaxis durations varied from none to ≥ 12 months. For D+/R− non‐lung SOTr, no prophylaxis with preemptive therapy only versus 3 months of prophylaxis was associated with higher risk of CMV infection and disease (adjusted incidence rate ratio [aIRR] [95% CI] 2.46 [1.69–3.57], and 2.82 [1.18–6.68]). Risk did not differ between 3 and 6 months of prophylaxis. For D+/R− lung transplant recipients, 3 versus 6 months of prophylaxis was associated with higher risk of CMV infection and high CMV DNAemia (2.74 [1.36–5.52] and 8.10 [1.89–41.90]), but not significantly higher risk of CMV disease. Irrespective of antiviral prophylaxis duration, incidence of CMV disease was lower among R+ compared to D+/R− SOTr. Conclusions: In a setting with CMV surveillance after prophylaxis, 3 months of antiviral prophylaxis seems adequate to prevent CMV disease in D+/R− non‐lung SOTr, whereas lung transplant recipients may benefit from longer duration of prophylaxis. Risk of CMV disease was low among R+ SOTr, irrespective of antiviral prophylaxis.
- 9 October 2026
- Published by Wiley in Transplant Infectious Disease
Open AccessProphylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study
Background: The optimal duration of cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients (SOTr) remains undetermined. We evaluated real‐life preventive strategies on the incidence of CMV disease in an international SOTr cohort. Methods: All CMV IgG donor (D)+/recipient (R)− or R+ SOTr in Zürich, Lausanne, and Copenhagen (2008–2022) were followed 12‐month post‐transplantation. Multivariable Poisson regression examined associations between antiviral prophylaxis duration and risk of CMV infection and CMV disease at time of infection diagnosis. Results: We included 3203 non‐lung (2057 kidney, 815 liver, 331 heart) and 620 lung transplant recipients. Strategies for CMV prophylaxis durations varied from none to ≥ 12 months. For D+/R− non‐lung SOTr, no prophylaxis with preemptive therapy only versus 3 months of prophylaxis was associated with higher risk of CMV infection and disease (adjusted incidence rate ratio [aIRR] [95% CI] 2.46 [1.69–3.57], and 2.82 [1.18–6.68]). Risk did not differ between 3 and 6 months of prophylaxis. For D+/R− lung transplant recipients, 3 versus 6 months of prophylaxis was associated with higher risk of CMV infection and high CMV DNAemia (2.74 [1.36–5.52] and 8.10 [1.89–41.90]), but not significantly higher risk of CMV disease. Irrespective of antiviral prophylaxis duration, incidence of CMV disease was lower among R+ compared to D+/R− SOTr. Conclusions: In a setting with CMV surveillance after prophylaxis, 3 months of antiviral prophylaxis seems adequate to prevent CMV disease in D+/R− non‐lung SOTr, whereas lung transplant recipients may benefit from longer duration of prophylaxis. Risk of CMV disease was low among R+ SOTr, irrespective of antiviral prophylaxis.
- 16 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (867)
Unanticipated global emergence and evolution of Pneumocystis jirovecii mutations and resistance driven by a human-targeted drug
Nearly all known cases of antimicrobial resistance have been linked to agents that directly target microbes. This paradigm overlooks other drivers of microbial evolution and resistance. Here, we report compelling evidence of resistance-associated mutations in Pneumocystis jirovecii , a high-priority fungal pathogen designated by WHO as having unknown resistance. These mutations emerged under selective pressure from mycophenolic acid (MPA), a widely used immunosuppressant not used for Pneumocystis pneumonia (PCP) treatment. A potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), MPA has been linked to altered P. jirovecii susceptibility in solid organ transplant (SOT) recipients. Genetic analysis of 163 P. jirovecii samples from PCP outbreaks in SOT recipients and nontransplant controls across six countries identified six impdh mutations, four of which were previously unreported. These mutations showed strong associations with prior MPA exposure, geographic segregation, and temporal shifts. They arose independently in 11 distinct strains worldwide between 2005 and 2019, with evidence of switching within and between strains, suggesting ongoing adaptive evolution. Structural modeling predicted that these mutations reduced IMPDH stability and MPA binding; accordingly, all mutations conferred MPA resistance in enzyme inhibition assays. Our findings uncover the unanticipated global emergence of multiple resistance-associated mutations in P. jirovecii driven by a human-targeted immunosuppressant, likely conferring a survival advantage in SOT recipients and facilitating transmission and outbreaks. These results challenge the current status quo on P. jirovecii ’s unknown resistance, calling for reevaluating immunosuppressive strategies and infection control measures and highlighting the broader potential for other pathogens to evolve under selective pressures imposed by human-targeted therapies.
- 16 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (867)
Unanticipated global emergence and evolution of Pneumocystis jirovecii mutations and resistance driven by a human-targeted drug
Nearly all known cases of antimicrobial resistance have been linked to agents that directly target microbes. This paradigm overlooks other drivers of microbial evolution and resistance. Here, we report compelling evidence of resistance-associated mutations in Pneumocystis jirovecii , a high-priority fungal pathogen designated by WHO as having unknown resistance. These mutations emerged under selective pressure from mycophenolic acid (MPA), a widely used immunosuppressant not used for Pneumocystis pneumonia (PCP) treatment. A potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), MPA has been linked to altered P. jirovecii susceptibility in solid organ transplant (SOT) recipients. Genetic analysis of 163 P. jirovecii samples from PCP outbreaks in SOT recipients and nontransplant controls across six countries identified six impdh mutations, four of which were previously unreported. These mutations showed strong associations with prior MPA exposure, geographic segregation, and temporal shifts. They arose independently in 11 distinct strains worldwide between 2005 and 2019, with evidence of switching within and between strains, suggesting ongoing adaptive evolution. Structural modeling predicted that these mutations reduced IMPDH stability and MPA binding; accordingly, all mutations conferred MPA resistance in enzyme inhibition assays. Our findings uncover the unanticipated global emergence of multiple resistance-associated mutations in P. jirovecii driven by a human-targeted immunosuppressant, likely conferring a survival advantage in SOT recipients and facilitating transmission and outbreaks. These results challenge the current status quo on P. jirovecii ’s unknown resistance, calling for reevaluating immunosuppressive strategies and infection control measures and highlighting the broader potential for other pathogens to evolve under selective pressures imposed by human-targeted therapies.
- Open Access
- 11 August 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70296
Hepatitis E Virus Infection in Swiss Transplant Recipients: Seroprevalence, Incidence, and the Role of Transfused Blood Products
Background: In Switzerland, hepatitis E virus (HEV) Genotype 3 is the leading cause of acute viral hepatitis and is mainly transmitted via contaminated pork, but also through solid organ transplantation and blood transfusion. Immunocompromised patients are particularly at risk, as chronic hepatitis may develop. This nationwide cross‐sectional study aimed to retrospectively assess HEV epidemiology in SOT and allogeneic hematopoietic stem cell transplant recipients. Methods: A total of 2942 patients from the Swiss Transplant Cohort Study sampled at transplantation date (T0) and at 1‐year follow‐up (T12) were tested for anti‐HEV IgG and HEV RNA. For seroconverted or HEV RNA‐positive patients, further analyses were performed, including characterization of samples collected 6 months posttransplantation (T6). Furthermore, 587 archived blood donor samples were retrospectively examined to investigate their potential role in HEV transmission. Results: The anti‐HEV IgG seroprevalence of 21.6% at T0 and 19.4% at T12 in transplant recipients was comparable to that of Swiss blood donors. However, the overall incidence of HEV RNA of 1:210 was more than 20‐fold higher, with 53% of infections persisting for 6 months or more. Except for one imported genotype 1g case, all infections were of Genotype 3, predominantly subtype 3h3, which is endemic in Switzerland. Notably, a transfusion‐transmitted HEV infection was identified. Conclusion: Given the increased susceptibility of transplant recipients to HEV and their reduced ability to clear the infection, surveillance and dietary advisory measures are crucial to reduce the risk of potentially deleterious outcomes. HEV screening of blood donors should be maintained as an important preventive measure.
- 11 August 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70296
Open AccessHepatitis E Virus Infection in Swiss Transplant Recipients: Seroprevalence, Incidence, and the Role of Transfused Blood Products
Background: In Switzerland, hepatitis E virus (HEV) Genotype 3 is the leading cause of acute viral hepatitis and is mainly transmitted via contaminated pork, but also through solid organ transplantation and blood transfusion. Immunocompromised patients are particularly at risk, as chronic hepatitis may develop. This nationwide cross‐sectional study aimed to retrospectively assess HEV epidemiology in SOT and allogeneic hematopoietic stem cell transplant recipients. Methods: A total of 2942 patients from the Swiss Transplant Cohort Study sampled at transplantation date (T0) and at 1‐year follow‐up (T12) were tested for anti‐HEV IgG and HEV RNA. For seroconverted or HEV RNA‐positive patients, further analyses were performed, including characterization of samples collected 6 months posttransplantation (T6). Furthermore, 587 archived blood donor samples were retrospectively examined to investigate their potential role in HEV transmission. Results: The anti‐HEV IgG seroprevalence of 21.6% at T0 and 19.4% at T12 in transplant recipients was comparable to that of Swiss blood donors. However, the overall incidence of HEV RNA of 1:210 was more than 20‐fold higher, with 53% of infections persisting for 6 months or more. Except for one imported genotype 1g case, all infections were of Genotype 3, predominantly subtype 3h3, which is endemic in Switzerland. Notably, a transfusion‐transmitted HEV infection was identified. Conclusion: Given the increased susceptibility of transplant recipients to HEV and their reduced ability to clear the infection, surveillance and dietary advisory measures are crucial to reduce the risk of potentially deleterious outcomes. HEV screening of blood donors should be maintained as an important preventive measure.
- Open Access
- 4 June 2026
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 28 (1)
The Infection Timeline in Solid Organ Transplantation: Lessons from the Swiss Transplant Cohort
Purpose of Review: Understanding the timeline of infections after solid organ transplantation is essential for prevention, diagnosis, and appropriate empiric therapy. Preventive strategies have substantially reduced some infections, while the increasing prevalence of multidrug-resistant organisms challenges traditional empiric approaches. Recent Findings: Contemporary epidemiology demonstrates a shift in post-transplant infections. Opportunistic infections have become uncommon, while bacterial infections now predominate, particularly those caused by Enterobacterales, non-fermenting gram-negative bacilli, and gram-positive pathogens. The success in the control of opportunistic infections is increasingly challenged by the rise of multidrug-resistant organisms. Summary: Strengthened strategies to prevent bacterial infections, especially those due to multidrug-resistant pathogens, are needed in solid organ transplant recipients.
- 4 June 2026
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 28 (1)
Open AccessThe Infection Timeline in Solid Organ Transplantation: Lessons from the Swiss Transplant Cohort
Purpose of Review: Understanding the timeline of infections after solid organ transplantation is essential for prevention, diagnosis, and appropriate empiric therapy. Preventive strategies have substantially reduced some infections, while the increasing prevalence of multidrug-resistant organisms challenges traditional empiric approaches. Recent Findings: Contemporary epidemiology demonstrates a shift in post-transplant infections. Opportunistic infections have become uncommon, while bacterial infections now predominate, particularly those caused by Enterobacterales, non-fermenting gram-negative bacilli, and gram-positive pathogens. The success in the control of opportunistic infections is increasingly challenged by the rise of multidrug-resistant organisms. Summary: Strengthened strategies to prevent bacterial infections, especially those due to multidrug-resistant pathogens, are needed in solid organ transplant recipients.
- Open Access
- 26 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70245
Recipient–Donor Sex Combinations and Posttransplant Infections: A Swiss Transplant Cohort Study
Background: Despite increasing interest in sex and gender in transplant medicine, the impact of recipient–donor sex combinations (RDSCs) on posttransplant infections, graft survival, and rejection remains unclear. To assess if RDSC is independently associated with infectious events in solid organ transplantion (SOT) recipients. Methods: This retrospective cohort study assessed a national prospectively maintained registry including six transplant centers. All adult patients, undergoing primary transplant of either heart, kidney, liver, or lung, between May 1, 2008, and December 31, 2021, were included. Endpoints were clinically significant infectious events (primary endpoint), graft survival, rejection, and overall survival within the first year. Patients were grouped as per RDSC. The primary statistical outcome of the organ‐specific, a priori known risk factor‐adjusted analyses are reported as incidence rate ratios (IRRs). Results: The cohort included 5033 recipients: 2886 (57.3%) kidney, 1224 (24.3%) liver, 515 (10.2%) lung, and 408 (8.1%) heart transplants, documenting 6067 infections. Recipient–donor sex mismatch was not associated with weighted posttransplant infection risk in heart (IRR: 1.06; 95% CI: 0.75, 1.48; p = 0.75), kidney (IRR: 1.03; 95% CI: 0.90, 1.17; p = 0.69), liver (IRR: 1.10; 95% CI: 0.81, 1.50; p = 0.52), or lung (IRR: 1.02; 95% CI: 0.82, 1.26; p = 0.89) recipients. Female kidney recipients had significantly higher infection rates than males (IRR: 1.50; 95% CI: 1.32, 1.71; p < 0.001), largely explained by urinary tract infections. One‐year graft survival, rejection, and overall survival were unaffected by RDSC across all organs. Conclusion: RDSC does not influence 1‐year SOT infectious outcome, as well as rejection or graft survival as exploratory outcomes. image
- 26 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70245
Open AccessRecipient–Donor Sex Combinations and Posttransplant Infections: A Swiss Transplant Cohort Study
Background: Despite increasing interest in sex and gender in transplant medicine, the impact of recipient–donor sex combinations (RDSCs) on posttransplant infections, graft survival, and rejection remains unclear. To assess if RDSC is independently associated with infectious events in solid organ transplantion (SOT) recipients. Methods: This retrospective cohort study assessed a national prospectively maintained registry including six transplant centers. All adult patients, undergoing primary transplant of either heart, kidney, liver, or lung, between May 1, 2008, and December 31, 2021, were included. Endpoints were clinically significant infectious events (primary endpoint), graft survival, rejection, and overall survival within the first year. Patients were grouped as per RDSC. The primary statistical outcome of the organ‐specific, a priori known risk factor‐adjusted analyses are reported as incidence rate ratios (IRRs). Results: The cohort included 5033 recipients: 2886 (57.3%) kidney, 1224 (24.3%) liver, 515 (10.2%) lung, and 408 (8.1%) heart transplants, documenting 6067 infections. Recipient–donor sex mismatch was not associated with weighted posttransplant infection risk in heart (IRR: 1.06; 95% CI: 0.75, 1.48; p = 0.75), kidney (IRR: 1.03; 95% CI: 0.90, 1.17; p = 0.69), liver (IRR: 1.10; 95% CI: 0.81, 1.50; p = 0.52), or lung (IRR: 1.02; 95% CI: 0.82, 1.26; p = 0.89) recipients. Female kidney recipients had significantly higher infection rates than males (IRR: 1.50; 95% CI: 1.32, 1.71; p < 0.001), largely explained by urinary tract infections. One‐year graft survival, rejection, and overall survival were unaffected by RDSC across all organs. Conclusion: RDSC does not influence 1‐year SOT infectious outcome, as well as rejection or graft survival as exploratory outcomes. image
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , 991-1003
Preformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis
The impact of preformed donor-specific antibodies (DSA) in liver transplantation (LT) remains controversial despite evidence linking their presence to an increased risk of early allograft damage, as well as antibody- and T-cell–mediated rejection. In this nationwide analysis, preformed DSA were assessed using single-antigen bead assays [positive if mean fluorescence intensity (MFI) ≥1000]. This study included all LT recipients enrolled in the Swiss Transplant Cohort Study (STCS) who underwent LT between 2014 and 2016. One-year post-LT outcomes, including cumulative allograft and patient survival, as well as the incidence of biliary, vascular, and infectious complications, were compared between DSA-positive (DSA+) and DSA-negative (DSA−) individuals. Among 321 LT performed in 306 patients, preformed DSA were detected in 92 (28.7%) and more frequently observed in patients with a history of prior transplantation ( p =0.008) or autoimmune liver disease ( p =0.036). Class I and II DSA were present in 48.9% and 71.1% of DSA+ cases, with concomitant class I and II DSA in 20.7%. The median (IQR) cumulative MFI (cMFI) of the preformed DSA was 3768 (1875–10,537), and 52.2% of DSA+ patients harbored multiple DSA. While overall patient survival did not differ between DSA+ and DSA− individuals, DSA+ patients with cMFI ≥5000 exhibited a higher incidence of allograft failure and biopsy-proven rejection. Multivariate analysis revealed that the presence of preformed DSA was independently associated with biliary complications (HR 2.26, 95% CI 1.17–4.37, p =0.02) but not with vascular or infectious complications. In summary, preformed DSA were associated with biliary complications, increased rejection, and reduced allograft survival. These findings suggest pre-transplant immunological risk assessment and the need for tailored immunosuppressive strategies in LT.
- 14 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , 991-1003
Open AccessPreformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis
The impact of preformed donor-specific antibodies (DSA) in liver transplantation (LT) remains controversial despite evidence linking their presence to an increased risk of early allograft damage, as well as antibody- and T-cell–mediated rejection. In this nationwide analysis, preformed DSA were assessed using single-antigen bead assays [positive if mean fluorescence intensity (MFI) ≥1000]. This study included all LT recipients enrolled in the Swiss Transplant Cohort Study (STCS) who underwent LT between 2014 and 2016. One-year post-LT outcomes, including cumulative allograft and patient survival, as well as the incidence of biliary, vascular, and infectious complications, were compared between DSA-positive (DSA+) and DSA-negative (DSA−) individuals. Among 321 LT performed in 306 patients, preformed DSA were detected in 92 (28.7%) and more frequently observed in patients with a history of prior transplantation ( p =0.008) or autoimmune liver disease ( p =0.036). Class I and II DSA were present in 48.9% and 71.1% of DSA+ cases, with concomitant class I and II DSA in 20.7%. The median (IQR) cumulative MFI (cMFI) of the preformed DSA was 3768 (1875–10,537), and 52.2% of DSA+ patients harbored multiple DSA. While overall patient survival did not differ between DSA+ and DSA− individuals, DSA+ patients with cMFI ≥5000 exhibited a higher incidence of allograft failure and biopsy-proven rejection. Multivariate analysis revealed that the presence of preformed DSA was independently associated with biliary complications (HR 2.26, 95% CI 1.17–4.37, p =0.02) but not with vascular or infectious complications. In summary, preformed DSA were associated with biliary complications, increased rejection, and reduced allograft survival. These findings suggest pre-transplant immunological risk assessment and the need for tailored immunosuppressive strategies in LT.
- 2 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (7) , 1529-1530
Towards an individualized prediction of infectious risk
- 2 April 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (7) , 1529-1530
Towards an individualized prediction of infectious risk
- Open Access
- 25 February 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (3) , e70190
The Role of Nontuberculous Mycobacteria in Patients With Cystic Fibrosis Advanced Lung Disease
Background: Despite decreased morbidity and mortality in patients with cystic fibrosis (CF) with CFTR modulators, a significant percentage still develop advanced lung disease. Nontuberculous mycobacteria (NTM) remain challenging pathogens with unclear effects on disease progression and post‐transplant outcome. Methods: NTM‐positive patients were identified from all CF patients treated at the University Hospitals of Zurich and Lausanne between 1998 and 2020. Disease course pre‐ and post‐transplant was recorded, and NTM‐positive patients were compared to patients without NTM infection for death or lung transplantation, as well as post‐transplant survival and development of chronic lung allograft dysfunction (CLAD). Results: Of 270 patients, 56 (20.7%) met criteria for NTM positivity (two independent cultures with the same organism), with Mycobacterium abscessus complex (MABSC) being the most common species (75.0%). Death or transplantation occurred in 12 of 56 (21.4%) NTM‐positive patients and 92 of 198 (46.5%) NTM‐negative patients (OR 3.17; 95% CI, 1.53–7.00; p = 0.001). Post‐transplant mortality was higher in the NTM‐positive cohort (3 (27.3%) vs. 12 (13.0%); HR, 4.01, 95% CI, 1.08–14.86; p = 0.024), while CLAD incidence did not differ significantly. Conclusion: NTM‐positive CF patients were associated with a lower pre‐transplant risk of death or transplantation. Post‐transplant mortality was higher in NTM‐positive patients, while no association between NTM infection and CLAD was observed. These findings indicate that favorable outcomes after lung transplantation are achievable in NTM‐positive patients. Thus, NTM‐infection should not be an absolute contraindication for lung transplantation, though careful individual assessment is essential due to the risk of serious complications. image
- 25 February 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (3) , e70190
Open AccessThe Role of Nontuberculous Mycobacteria in Patients With Cystic Fibrosis Advanced Lung Disease
Background: Despite decreased morbidity and mortality in patients with cystic fibrosis (CF) with CFTR modulators, a significant percentage still develop advanced lung disease. Nontuberculous mycobacteria (NTM) remain challenging pathogens with unclear effects on disease progression and post‐transplant outcome. Methods: NTM‐positive patients were identified from all CF patients treated at the University Hospitals of Zurich and Lausanne between 1998 and 2020. Disease course pre‐ and post‐transplant was recorded, and NTM‐positive patients were compared to patients without NTM infection for death or lung transplantation, as well as post‐transplant survival and development of chronic lung allograft dysfunction (CLAD). Results: Of 270 patients, 56 (20.7%) met criteria for NTM positivity (two independent cultures with the same organism), with Mycobacterium abscessus complex (MABSC) being the most common species (75.0%). Death or transplantation occurred in 12 of 56 (21.4%) NTM‐positive patients and 92 of 198 (46.5%) NTM‐negative patients (OR 3.17; 95% CI, 1.53–7.00; p = 0.001). Post‐transplant mortality was higher in the NTM‐positive cohort (3 (27.3%) vs. 12 (13.0%); HR, 4.01, 95% CI, 1.08–14.86; p = 0.024), while CLAD incidence did not differ significantly. Conclusion: NTM‐positive CF patients were associated with a lower pre‐transplant risk of death or transplantation. Post‐transplant mortality was higher in NTM‐positive patients, while no association between NTM infection and CLAD was observed. These findings indicate that favorable outcomes after lung transplantation are achievable in NTM‐positive patients. Thus, NTM‐infection should not be an absolute contraindication for lung transplantation, though careful individual assessment is essential due to the risk of serious complications. image
- 3 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1482-1490
Frequency of viral monitoring to detect cytomegalovirus infection and prevent disease in solid organ transplant recipients: An international, multicenter cohort study
- 3 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1482-1490
Frequency of viral monitoring to detect cytomegalovirus infection and prevent disease in solid organ transplant recipients: An international, multicenter cohort study
- Open Access
- 2 February 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (2)
Clinical Presentation, Risk Factors and Outcome of Non-Tuberculous Mycobacteria Infection in Hematopoietic Stem-Cell Transplantation: A Multinational Case-Control Study
Background: The clinical and microbiological features of infection due to non-tuberculous mycobacteria (NTM) after hematopoietic stem-cell transplantation (HSCT) remain poorly understood. Methods: We performed a retrospective, multinational case-control study that included HSCT recipients (≥12 years) diagnosed with NTM disease between January 2008 and December 2018. Controls were HSCT recipients with no evidence of NTM disease, matched (1:2 ratio) by participating center and post-transplant survival. Logistic regression on matched pairs was used to investigate risk factors for NTM disease. Results: We included 25 cases of NTM disease. The most common HSCT type was allogeneic from unrelated donor (72.0%) after myeloablative conditioning (76.0%). Predominant hematological conditions were acute myelogenous leukemia (28.0%) and myelodysplastic syndrome (24.0%). Most patients (88.0%) had previously received immunosuppressive therapy. The most common species identified were Mycobacterium avium complex (64.0%) and rapidly growing mycobacteria (20.0%). Most patients (68.0%) had pulmonary disease. All but one received antimycobacterial therapy for a median of 267.5 days. Macrolides (83.3%), rifamycins (58.3%) and ethambutol (62.5%) were the most commonly used drugs. Four patients (16.7%) developed adverse events requiring therapy discontinuation. All-cause and attributable mortality rates were 28.0% and 4.0%, respectively. One patient experienced relapse after 464 days. Diagnosis of a non-NTM infection (adjusted odds ratio [aOR]: 3.11; 95% confidence interval [95% CI]: 1.25–7.78) and corticosteroid therapy (aOR: 2.88; 95% CI: 1.16–7.17), both within the previous 90 days, were associated with NTM disease. Conclusions: NTM disease is a serious complication among heavily immunocompromised HSCT recipients associated with prior non-NTM infection and corticosteroid therapy.
- 2 February 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (2)
Open AccessClinical Presentation, Risk Factors and Outcome of Non-Tuberculous Mycobacteria Infection in Hematopoietic Stem-Cell Transplantation: A Multinational Case-Control Study
Background: The clinical and microbiological features of infection due to non-tuberculous mycobacteria (NTM) after hematopoietic stem-cell transplantation (HSCT) remain poorly understood. Methods: We performed a retrospective, multinational case-control study that included HSCT recipients (≥12 years) diagnosed with NTM disease between January 2008 and December 2018. Controls were HSCT recipients with no evidence of NTM disease, matched (1:2 ratio) by participating center and post-transplant survival. Logistic regression on matched pairs was used to investigate risk factors for NTM disease. Results: We included 25 cases of NTM disease. The most common HSCT type was allogeneic from unrelated donor (72.0%) after myeloablative conditioning (76.0%). Predominant hematological conditions were acute myelogenous leukemia (28.0%) and myelodysplastic syndrome (24.0%). Most patients (88.0%) had previously received immunosuppressive therapy. The most common species identified were Mycobacterium avium complex (64.0%) and rapidly growing mycobacteria (20.0%). Most patients (68.0%) had pulmonary disease. All but one received antimycobacterial therapy for a median of 267.5 days. Macrolides (83.3%), rifamycins (58.3%) and ethambutol (62.5%) were the most commonly used drugs. Four patients (16.7%) developed adverse events requiring therapy discontinuation. All-cause and attributable mortality rates were 28.0% and 4.0%, respectively. One patient experienced relapse after 464 days. Diagnosis of a non-NTM infection (adjusted odds ratio [aOR]: 3.11; 95% confidence interval [95% CI]: 1.25–7.78) and corticosteroid therapy (aOR: 2.88; 95% CI: 1.16–7.17), both within the previous 90 days, were associated with NTM disease. Conclusions: NTM disease is a serious complication among heavily immunocompromised HSCT recipients associated with prior non-NTM infection and corticosteroid therapy.